TrialCancer medicine2018

A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors.

Alejandro Zulbaran-Rojas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.